What’s new in medical therapy of type 2 diabetes?
Autor(a) principal: | |
---|---|
Data de Publicação: | 2011 |
Outros Autores: | , |
Tipo de documento: | Artigo |
Idioma: | por |
Título da fonte: | Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
DOI: | 10.34632/cadernosdesaude.2011.3043 |
Texto Completo: | https://doi.org/10.34632/cadernosdesaude.2011.3043 |
Resumo: | Type 2 diabetes mellitus is a progressive disease with an increasing prevalence. The ideal antidiabetic agent is the one that allows good glycaemic control and is able to change the natural history of the disease, with consequent reduction of the morbidity and mortality associated to the complications of diabetes. Such antidiabetic agent has yet to demonstrate a good safety profile, namely absence of hypoglycaemias, weight gain or cardiovascular risk increase. After decades of stagnation, remarkable progress in diabetes therapy has been done in recent years. Some of the new antidiabetic agents are already in the market, namely incretin based therapies and amylin analogs, and other are still in investigation. Incretin based therapies (glucose‑like peptide‑1 analogs and dipeptidil‑peptidase 4 inhibitors) showed to be effective in A1c reduction, with low risk of hypoglycaemia and no weight gain (or even weight loss in the former). They also seem to slow disease progression in early stages and to have an anti‑atherogenic action. The new anti‑diabetics, namely incretin based therapies, are promising, but still have to demonstrate long‑term effectiveness and safety as well as good cost‑effectiveness. |
id |
RCAP_b28e88661b7ac1f3ec0ab9a318a74782 |
---|---|
oai_identifier_str |
oai:ojs.revistas.ucp.pt:article/3043 |
network_acronym_str |
RCAP |
network_name_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
repository_id_str |
7160 |
spelling |
What’s new in medical therapy of type 2 diabetes?O que há de novo na terapêutica médica da diabetes mellitus tipo 2?Type 2 diabetes mellitus is a progressive disease with an increasing prevalence. The ideal antidiabetic agent is the one that allows good glycaemic control and is able to change the natural history of the disease, with consequent reduction of the morbidity and mortality associated to the complications of diabetes. Such antidiabetic agent has yet to demonstrate a good safety profile, namely absence of hypoglycaemias, weight gain or cardiovascular risk increase. After decades of stagnation, remarkable progress in diabetes therapy has been done in recent years. Some of the new antidiabetic agents are already in the market, namely incretin based therapies and amylin analogs, and other are still in investigation. Incretin based therapies (glucose‑like peptide‑1 analogs and dipeptidil‑peptidase 4 inhibitors) showed to be effective in A1c reduction, with low risk of hypoglycaemia and no weight gain (or even weight loss in the former). They also seem to slow disease progression in early stages and to have an anti‑atherogenic action. The new anti‑diabetics, namely incretin based therapies, are promising, but still have to demonstrate long‑term effectiveness and safety as well as good cost‑effectiveness.A diabetes mellitus tipo 2 é uma doença progressiva com uma prevalência crescente. O antidiabético ideal será aquele que permita um bom controlo glicémico e altere a história natural da doença, com consequente diminuição da morbilidade e mortalidade associadas às complicações da doença. Terá ainda que demonstrar um bom perfil de segurança, nomeadamente ausência de hipoglicemias, de ganho de peso ou de aumento do risco cardiovascular. Após décadas de estagnação, a terapêutica da diabetes tem conhecido notáveis progressos nos últimos anos, que se traduziram no desenvolvimento de novas classes de fármacos, algumas delas já comercializadas, como as terapêuticas baseadas nas incretinas e os análogos da amilina, e outras em fase de investigação. As terapêuticas baseadas nas incretinas (análogos do glucose‑like peptide‑1 e inibidores da dipeptidil‑peptidase 4) mostraram‑se eficazes na redução da A1c, com baixo risco de hipoglicemias e ausência de ganho de peso (ou mesmo perda, no caso dos primeiros). Parecem ainda poder atrasar a progressão da doença em fases precoces e ter uma acção anti‑aterogenica. Os novos fármacos, nomeadamente os baseados nas incretinas, são promissores, mas terão ainda que demonstrar eficácia e segurança a longo prazo e uma boa relação custo‑eficacia.Universidade Católica Portuguesa2011-12-01info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/articleapplication/pdfhttps://doi.org/10.34632/cadernosdesaude.2011.3043https://doi.org/10.34632/cadernosdesaude.2011.3043Cadernos de Saúde; Vol 4 No Especial (2011): Obesidade; 83-87Cadernos de Saúde; v. 4 n. Especial (2011): Obesidade; 83-872795-43581647-055910.34632/cadernosdesaude.2011.4.Especialreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAPporhttps://revistas.ucp.pt/index.php/cadernosdesaude/article/view/3043https://revistas.ucp.pt/index.php/cadernosdesaude/article/view/3043/2942Direitos de Autor (c) 2011 M. J. Matos, P. Freitas, D. Carvalhohttp://creativecommons.org/licenses/by/4.0info:eu-repo/semantics/openAccessMatos, M. J.Freitas, P.Carvalho, D.2023-10-03T15:47:44Zoai:ojs.revistas.ucp.pt:article/3043Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-19T20:33:00.013950Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse |
dc.title.none.fl_str_mv |
What’s new in medical therapy of type 2 diabetes? O que há de novo na terapêutica médica da diabetes mellitus tipo 2? |
title |
What’s new in medical therapy of type 2 diabetes? |
spellingShingle |
What’s new in medical therapy of type 2 diabetes? What’s new in medical therapy of type 2 diabetes? Matos, M. J. Matos, M. J. |
title_short |
What’s new in medical therapy of type 2 diabetes? |
title_full |
What’s new in medical therapy of type 2 diabetes? |
title_fullStr |
What’s new in medical therapy of type 2 diabetes? What’s new in medical therapy of type 2 diabetes? |
title_full_unstemmed |
What’s new in medical therapy of type 2 diabetes? What’s new in medical therapy of type 2 diabetes? |
title_sort |
What’s new in medical therapy of type 2 diabetes? |
author |
Matos, M. J. |
author_facet |
Matos, M. J. Matos, M. J. Freitas, P. Carvalho, D. Freitas, P. Carvalho, D. |
author_role |
author |
author2 |
Freitas, P. Carvalho, D. |
author2_role |
author author |
dc.contributor.author.fl_str_mv |
Matos, M. J. Freitas, P. Carvalho, D. |
description |
Type 2 diabetes mellitus is a progressive disease with an increasing prevalence. The ideal antidiabetic agent is the one that allows good glycaemic control and is able to change the natural history of the disease, with consequent reduction of the morbidity and mortality associated to the complications of diabetes. Such antidiabetic agent has yet to demonstrate a good safety profile, namely absence of hypoglycaemias, weight gain or cardiovascular risk increase. After decades of stagnation, remarkable progress in diabetes therapy has been done in recent years. Some of the new antidiabetic agents are already in the market, namely incretin based therapies and amylin analogs, and other are still in investigation. Incretin based therapies (glucose‑like peptide‑1 analogs and dipeptidil‑peptidase 4 inhibitors) showed to be effective in A1c reduction, with low risk of hypoglycaemia and no weight gain (or even weight loss in the former). They also seem to slow disease progression in early stages and to have an anti‑atherogenic action. The new anti‑diabetics, namely incretin based therapies, are promising, but still have to demonstrate long‑term effectiveness and safety as well as good cost‑effectiveness. |
publishDate |
2011 |
dc.date.none.fl_str_mv |
2011-12-01 |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
https://doi.org/10.34632/cadernosdesaude.2011.3043 https://doi.org/10.34632/cadernosdesaude.2011.3043 |
url |
https://doi.org/10.34632/cadernosdesaude.2011.3043 |
dc.language.iso.fl_str_mv |
por |
language |
por |
dc.relation.none.fl_str_mv |
https://revistas.ucp.pt/index.php/cadernosdesaude/article/view/3043 https://revistas.ucp.pt/index.php/cadernosdesaude/article/view/3043/2942 |
dc.rights.driver.fl_str_mv |
Direitos de Autor (c) 2011 M. J. Matos, P. Freitas, D. Carvalho http://creativecommons.org/licenses/by/4.0 info:eu-repo/semantics/openAccess |
rights_invalid_str_mv |
Direitos de Autor (c) 2011 M. J. Matos, P. Freitas, D. Carvalho http://creativecommons.org/licenses/by/4.0 |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.publisher.none.fl_str_mv |
Universidade Católica Portuguesa |
publisher.none.fl_str_mv |
Universidade Católica Portuguesa |
dc.source.none.fl_str_mv |
Cadernos de Saúde; Vol 4 No Especial (2011): Obesidade; 83-87 Cadernos de Saúde; v. 4 n. Especial (2011): Obesidade; 83-87 2795-4358 1647-0559 10.34632/cadernosdesaude.2011.4.Especial reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação instacron:RCAAP |
instname_str |
Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
instacron_str |
RCAAP |
institution |
RCAAP |
reponame_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
collection |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
repository.name.fl_str_mv |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
repository.mail.fl_str_mv |
|
_version_ |
1822183398440960000 |
dc.identifier.doi.none.fl_str_mv |
10.34632/cadernosdesaude.2011.3043 |